ProCE Banner Activity

ART in Conception and Pregnancy: What Have We Learned?

Conference Coverage
Clinical Thought
Seven years after the FDA approval of dolutegravir and 2 years after the reporting of a potential association with neural tube defects when taken at/near the time of conception, do we finally have sufficient data on the use of this highly effective HIV therapy in women during conception and pregnancy?

Released: August 14, 2020

Expiration: August 13, 2021

No longer available for credit.

Share

Faculty

Chloe Orkin

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by:

Gilead

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

AIDS 2020

ProCE Banner

IAS 2018

ProCE Banner

Faculty Disclosure

Primary Author

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD, has disclosed that she has received funds for research support, consulting fees, and fees for non-CME/CE services from Gilead Sciences, GlaxoSmithKline, Janssen, MSD, and ViiV Healthcare.